TG Therapeutics
TGTX
197 hedge funds and large institutions have $1.11B invested in TG Therapeutics in 2022 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 64 increasing their positions, 57 reducing their positions, and 25 closing their positions.
87% more capital invested
Capital invested by funds: $595M → $1.11B (+$515M)
60% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 25
51% more call options, than puts
Call options by funds: $79.4M | Put options by funds: $52.5M
12% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 57
8% more funds holding
Funds holding: 183 → 197 (+14)
4.73% less ownership
Funds ownership: 68.97% → 64.24% (-4.7%)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$16.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$11.8M |
| 3 |
D.E. Shaw & Co
New York
|
+$10.9M |
| 4 |
Alkeon Capital Management
New York
|
+$10.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$24.6M |
| 2 |
DM
Deerfield Management
New York
|
-$15.9M |
| 3 |
6CM
683 Capital Management
New York
|
-$11.1M |
| 4 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$10.5M |
| 5 |
State Street
Boston,
Massachusetts
|
-$9.69M |
TGTX Hedge Fund Activity: Q4 2022 in Review
197 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2022, worth a combined $1.11B — up 87% from $595M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new TGTX positions and 25 closed out — a net gain of 15 holders — while 64 added to existing stakes and 57 trimmed.
The largest buyer was Millennium Management, adding an estimated $16.2M. The largest seller was Maverick Capital, cutting an estimated $24.6M.
- 197 institutional investors held TG Therapeutics (TGTX) as of Q4 2022, up from 183 in Q3 2022.
- Funds reported $1.11B of TG Therapeutics stock for Q4 2022, up 87% quarter-over-quarter.
- 40 funds opened new TG Therapeutics positions in Q4 2022 and 25 closed out, a net change of +15 holders.
- The largest TG Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $16.2M added.
- The largest TG Therapeutics seller in Q4 2022 was Maverick Capital, an estimated $24.6M sold.
Based on aggregated 13F filings for Q4 2022.